Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
Ventyx Biosciences (VTYX) Stock Price & Analysis
243 Followers
VTYX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.87 - $38.20
Previous Close$2.56
Volume931.60K
Average Volume (3M)1.07M
Market Cap
$180.48M
Enterprise Value-$59.24M
Total Cash (Recent Filing)$252.22M
Total Debt (Recent Filing)$12.51M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 12, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.24
Shares Outstanding70,499,332
10 Day Avg. Volume1,211,769
30 Day Avg. Volume1,073,588
Standard Deviation0.52
R-Squared0.00354
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)0.73
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$12.33Price Target Upside334.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Ventyx Biosciences News
PremiumCompany Announcements
Ventyx Biosciences Reveals Promising Obesity Treatment Data
PremiumCompany Announcements
Ventyx Biosciences Names Matthew Moore New COO
Bulls Say, Bears Say
Bulls Say
Cardiovascular BenefitsThe data generated in this study of NT-0796 show improvements in inflammatory and metabolic biomarkers of CV risk that go beyond that seen with antibody and peptide therapies.
EfficacyMore than 75% of subjects dosed with NT-0796 achieved a CRP reduction to <2 mg/L by Day 28, compared to less than 25% in the placebo group.
Weight LossVentyx would trade up considerably if NT-0796 demonstrates at least 3% weight loss given the clear readthrough and low valuation.
Bears Say
Stock PerformanceShares were down -35% after VTX3232's preclinical data were reported.
Study Duration And DetailsThe results have limited significance as the study was conducted over only 28 days with minimal details provided.
Weight Reduction ComparisonVTX3232 body weight reduction appears lower than NodThera's NT-0796 and semaglutide.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $1.86 and its highest was $38.20 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Currently, no data Available
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Aug 12, 2024 which is in 21 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on May 09, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.681 by $0.061.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -$0.58.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 70,499,330 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.681. Following the earnings report the stock price went down -8.705%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Among the largest hedge funds holding Ventyx Biosciences’s share is Deerfield Management Company, LP. It holds Ventyx Biosciences’s shares valued at 19M.
---
Ventyx Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.33 (334.15% Upside)
$12.33 (334.15% Upside)
Blogger Sentiment
Neutral
VTYX Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 6.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.74%
12-Months-Change
Fundamentals
Return on Equity
-56.76%
Trailing 12-Months
Asset Growth
-14.67%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
---
VTYX Earnings Call
Q1 2024
0:00 / 0:00
---
VTYX Stock 12 Month Forecast
Average Price Target
$12.33
▲(334.15% Upside)
Technical Analysis
Best Analysts Covering VTYX
1 Year
1 Year Success Rate
6/21 ratings generated profit
1 Year Average Return
-13.33%
reiterated a buy rating last month
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -13.33% per trade.
---